Supporting the implementation of new treatment strategies in MS into clinical practice

This is the PPA version of the course. If you would prefer to take the non-PPA version of the course please click here

Faculty

Professor Patrick Vermersch, Vice Dean, University of Lille, CHRU de Lille, Lille International Research Inflammation Centre (LIRIC), Lille, France

Professor Antonio Uccelli, Professor of Neurology, Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Università di Genova, Italy

Professor Tobias Derfuss, Professor of Medicine and Senior Physician, Departments of Neurology and Biomedicine at University Clinic, Basel, Switzerland

Professor Gavin Giovannoni, Chair of Neurology, Blizard Institute, Queen Mary University of London, London, United Kingdom

Course overview

The programme first establishes your current practice, takes you through a six module e-learning course (including content from the UEMS/EACCME-accredited meeting “Integrating Innovations in the Treatment of Multiple Sclerosis into Clinical Practice”) and then provides a structured, self-reflective tool to help you implement new treatment strategies in your own clinical practice

Target audience

This educational activity is intended for any healthcare professionals involved in the treatment of patients with multiple sclerosis

Learning objectives

Upon completing of the programme, participants should be able to:

Understand the evolution of the multiple sclerosis treatment landscape over the last 25 years, in particular how our evolving understanding of the disease has guided the development of new therapies

Describe the current and new strategies for treating multiple sclerosis, including the use of new agents

Identify the risks and benefits of these newer treatment strategies and reflect on your own patient interactions, in comparison to your peers, when implementing them in daily practice

Funding

This programme has been partly supported by an independent educational grant from Merck KGaA, Darmastadt, Germany

Accreditation statement

The e-learning course, Supporting the implementation of new treatment strategies in MS into clinical practice, developed and organized by Clinically Current, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME^®) with 2 European CME credits (ECMEC^®s) to provide the following CME activity for medical specialists. Each medical specialist should claim only those hours of credit that he/she actually spent on the educational materials.

The EACCME^® is an institution of the European Union of Medical Specialists (UEMS). Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits^TM.

Information on the process to convert EACCME^® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Multiple Sclerosis Personal Practice Assessment: Baseline Questionnaire
If you've opted to participate in the PPA, please begin by completing this questionnaire.

This is the baseline questionnaire. Please answer the following questions based on what you currently do in your practice.

You will need to complete your baseline questionnaire before you proceed with learning modules 1-6.

Once you’ve completed your baseline questionnaire and have finished learning modules 1-6, you will be given access to your in-clinic questionnaires.

All results are collated anonymously.
- Multiple Sclerosis Personal Practice Assessment Questionnaire
Learning Modules 1-6
Multiple Sclerosis Personal Practice Assessment: in-clinic questionnaires
Here are your six in-clinic questionnaires.
Please complete one in-clinic questionnaire for six of your MS-specific patients. You must complete six questionnaires in total, one for each individual patient consultation. We recommend that you complete the questionnaire as soon as possible after each appointment.
Please note that if your patient reports any treatment-related adverse events it is your responsibility to report them according to your local guidelines.
- In-Clinic Questionnaire 1
  Restricted Not available unless:
  The activity Module 1: The changing landscape: 25 years of progress in MS therapy is marked complete
  The activity Module 2: The evolving view of neuroinflammation in MS is marked complete
  The activity Module 4: Newer immunomodulatory therapies in MS is marked complete
  The activity Module 5: Immune reconstitution therapy is marked complete
  The activity Module 3: Mechanisms of action: newer MS therapies is marked complete
  The activity Module 6: Case Studies is marked complete
- In-Clinic Questionnaire 2
  Restricted Not available unless: The activity In-Clinic Questionnaire 1 is marked complete
- In-Clinic Questionnaire 3
  Restricted Not available unless: The activity In-Clinic Questionnaire 2 is marked complete
- In-Clinic Questionnaire 4
  Restricted Not available unless: The activity In-Clinic Questionnaire 3 is marked complete
- In-Clinic Questionnaire 5
  Restricted Not available unless: The activity In-Clinic Questionnaire 4 is marked complete
- In-Clinic Questionnaire 6
  Restricted Not available unless: The activity In-Clinic Questionnaire 5 is marked complete
Evaluation Survey
- Take the evaluation survey Questionnaire
  Restricted Not available unless: The activity In-Clinic Questionnaire 6 is marked complete
Certification
- Certificate Custom certificate CC
  Restricted Not available unless: The activity Take the evaluation survey is marked complete

Faculty

Course overview

Target audience

Learning objectives

Funding

Accreditation statement

Multiple Sclerosis Personal Practice Assessment: Baseline Questionnaire

If you've opted to participate in the PPA, please begin by completing this questionnaire.

Learning Modules 1-6

Multiple Sclerosis Personal Practice Assessment: in-clinic questionnaires

Evaluation Survey

Certification